aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
CeleCor Therapeutics, founded with a mission to revolutionize heart attack treatment, focuses on developing novel small molecule inhibitors. Their flagship product, RUC-4, is designed as a first-response treatment for segment elevated myocardial infarction (STEMI). This innovative thrombolytic agent can be administered subcutaneously via an auto-injector, aiming to reduce mortality and prevent subsequent heart failure. CeleCor targets the acute cardiovascular care market, emphasizing rapid intervention to save lives.
Key figures affiliated with CeleCor Therapeutics include leading cardiologists and pharmaceutical experts who have contributed to its groundbreaking research and development. The company has attracted significant investment from venture capital firms specializing in biotech innovations. Among its notable achievements, CeleCor has successfully advanced RUC-4 through critical stages of clinical development, demonstrating its potential to transform emergency cardiac care. The impact of CeleCor's work promises to significantly improve survival rates and outcomes for heart attack patients worldwide.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Therapeutics, Inhibitors
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Americas
When was CeleCor Therapeutics founded?
CeleCor Therapeutics was founded in 2017.
Where is CeleCor Therapeutics’s headquarters located?
CeleCor Therapeutics’s headquarters is located in San Diego, CA, US.
When was CeleCor Therapeutics’s last funding round?
CeleCor Therapeutics’s most recent funding round was for $17.8M (USD) in March 2022.
How many employees does CeleCor Therapeutics have?
CeleCor Therapeutics has 6 employees as of Feb 5, 2024.
How much has CeleCor Therapeutics raised to-date?
As of July 05, 2023, CeleCor Therapeutics has raised a total of $18.8M (USD) since Mar 8, 2022.
Add Comparison
Total Raised to Date
$18.8M
USD
Last Update Mar 8, 2022
Last Deal Details
$17.8M
USD
Mar 8, 2022
Series Unknown
Total Employees Over Time
6
As of Feb 2024
CeleCor Therapeutics Address
San Diego,
California
92134
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts